Summary & Overview
CPT 0304U: Normoxic BioChip Adhesion Test for Sickle Cell Disease
CPT code 0304U identifies a proprietary laboratory test — the Normoxic BioChip Adhesion assay from BioChip Labs™ — that measures red blood cell adhesion under normal oxygen conditions using a microfluidic biochip. As a PLA code, 0304U applies to a single manufacturer-specific test and signals an emerging, specialized diagnostic modality relevant to sickle cell disease (SCD) therapeutic evaluation. Nationally, PLA codes like 0304U matter because they track novel laboratory technologies and support appropriate claims submission, coverage determinations, and utilization monitoring for specialized tests.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise information on the clinical purpose and testing context of 0304U, payer coverage considerations at a high level, and operational benchmarks where available. The publication provides a clear description of the service type and typical sites of service, highlights implications for laboratory billing and claims processing when a single-source PLA code is used, and outlines what data is available versus where input was not provided. The content is intended to inform billing staff, laboratory managers, and policy analysts about the code’s clinical context and administrative treatment without offering clinical recommendations.
Billing Code Overview
CPT code 0304U is a Proprietary Laboratory Analyses (PLA) code for the Normoxic BioChip Adhesion test from BioChip Labs™. The test uses a whole blood specimen at normal oxygen levels to evaluate red blood cell (RBC) adhesion to specific molecules found in the blood vessel lining using a microfluidic biochip. It is intended to help evaluate possible therapies for sickle cell disease (SCD).
Service type: Laboratory — specialized microfluidic adhesion assay
Typical site of service: Clinical laboratory or specialized diagnostic testing laboratory
Clinical & Coding Specifications
Clinical Context
A 26-year-old adult with sickle cell disease (SCD) is enrolled in a clinical trial evaluating novel anti-adhesive therapies. The patient presents to an outpatient specialty laboratory or clinical research center for phlebotomy. A whole blood specimen is collected under ambient (normoxic) conditions into the appropriate tube and transported to the testing laboratory. The laboratory performs the proprietary Normoxic BioChip Adhesion assay (0304U) using a microfluidic biochip to quantify red blood cell (RBC) adhesion to endothelial- or extracellular matrix–derived ligands. Results are used by the treating hematologist and study investigators to assess baseline adhesion phenotype, monitor response to investigational therapy, or stratify subjects for therapeutic arms. Typical site of service includes an outpatient phlebotomy laboratory, hospital outpatient clinic, or dedicated research laboratory with courier transport. Common clinical workflow: patient check-in → consent for research testing or order entry for clinical testing → venipuncture (whole blood collection) → specimen labeling and transport at normoxic conditions → performance of 0304U in the licensed laboratory → generation of quantitative adhesion report integrated into the study database or electronic medical record for the treating hematologist and trial team.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |